• Spirocyclic POM Analogues Targeting MmpL3 in Tuberculosis Re

  2026-06-10

  This study introduces spirocyclic phenyl oxazole methyl (POM) analogues as potent inhibitors of Mycobacterium tuberculosis, with a focus on the MmpL3 transporter—a target without clinically approved drugs. The lead compound demonstrated sub-micromolar activity against clinical isolates, offering hope for new strategies against drug-resistant TB.

• PTT and CD47 Blockade Synergy in OSCC: Mechanisms and Implic

  2026-06-10

  The referenced study demonstrates that combining photothermal therapy (PTT) with CD47 blockade markedly enhances macrophage-mediated clearance of oral squamous cell carcinoma (OSCC). This synergy is driven by PTT-induced calreticulin exposure and extracellular matrix remodeling, offering a dual mechanism to overcome immune evasion and physical barriers in the tumor microenvironment.

• Transmission Dynamics of Carbapenemase Genes in CREC During

  2026-06-09

  This study characterizes the genetic landscape and transferability of carbapenemase-encoding genes (CEGs) in carbapenem-resistant Enterobacter cloacae (CREC) isolates from eight teaching hospitals in Guangdong, China, collected during the COVID-19 pandemic. The findings reveal high rates of multidrug resistance, predominant plasmid-mediated blaNDM-1 carriage, and efficient horizontal gene transfer, highlighting urgent challenges for infection control and translational antibiotic research.

• Capsazepine Targets MCL1 to Reverse Tamoxifen Resistance in

  2026-06-09

  This study identifies capsazepine as a novel MCL1 inhibitor capable of overcoming tamoxifen resistance in estrogen receptor-positive breast cancer. Through integrated virtual and experimental screening, direct MCL1 binding, and synergy with tamoxifen, capsazepine offers a mechanistically validated strategy to combat endocrine therapy failure.

• MLN8237 (Alisertib): Precision Aurora A Inhibition in Cancer

  2026-06-08

  MLN8237 (Alisertib) offers researchers a highly selective, ATP-competitive Aurora A kinase inhibitor for advanced cancer biology workflows. When optimized, this tool enables robust apoptosis induction and precise dissection of cell cycle and trained immunity mechanisms—empowering translational studies in tumor growth inhibition and immune modulation.

• ampC/ampD Mutations Drive P. aeruginosa Resistance to C/T: P

  2026-06-08

  This study provides a rigorous dissection of ceftolozane-tazobactam resistance in Pseudomonas aeruginosa, linking specific ampC and ampD mutations to quantifiable shifts in drug susceptibility. By applying semi-mechanistic PKPD modeling, the authors differentiate initial and adaptive resistance mechanisms, offering precision insights for antimicrobial research and resistance monitoring.

• Carbapenemase Gene Transmission in CREC: Insights from Guang

  2026-06-07

  This study systematically characterizes the prevalence, genetic diversity, and transmission mechanisms of carbapenemase-encoding genes in carbapenem-resistant Enterobacter cloacae (CREC) across eight hospitals in Guangdong, China. The findings reveal predominant plasmid-mediated blaNDM-1 dissemination, high multidrug resistance, and significant epidemiological trends, offering important context for ongoing antimicrobial resistance research.

• Ceftolozane/Tazobactam and Meropenem: Advances in Gram-Negat

  2026-06-06

  The reference study evaluates ceftolozane/tazobactam, a novel cephalosporin/β-lactamase inhibitor, for complicated Gram-negative infections. Its mechanistic and pharmacodynamic innovations set new benchmarks for treating resistant pathogens, with significant implications for translational infection modeling and comparative research using β-lactam antibiotic carbapenems like Meropenem.

• Oral Faropenem Sodium: AMR Risks and Research Implications

  2026-06-05

  The reference study details how widespread oral faropenem sodium use, particularly in India, is contributing to antimicrobial resistance (AMR) and cross-resistance with vital carbapenems. It underscores the urgent need for rational antibiotic use and highlights gaps in susceptibility testing standards, providing key context for researchers investigating penem antibiotics and AMR mechanisms.

• Ceftazidime in Translational Research: Mechanism and Strateg

  2026-06-05

  Explore how Ceftazidime, a third-generation cephalosporin, empowers translational researchers to confront multidrug-resistant Gram-negative infections—particularly in respiratory models—by integrating mechanistic insights, evidence-based protocol design, and strategic considerations in the era of rapidly evolving resistance.

• Torin2: Advancing mTOR Pathway Inhibition in Cancer Models

  2026-06-04

  Explore how Torin2, a potent mTOR inhibitor, redefines cancer research by enabling advanced interrogation of mTOR signaling with unmatched selectivity. This article uncovers practical assay strategies and highlights new mechanistic insights for experimental oncology.

• Penicillin G Sodium: Advanced Mechanisms and Translational I

  2026-06-04

  Explore the advanced science of Penicillin G Sodium, a natural penicillin antibiotic. This article uncovers its molecular mechanisms, translational applications, and assay optimization insights distinct from previous guides.

• CD44-Mediated Metabolic Rewiring: A Target in IDH-Mutant AML

  2026-06-03

  This study reveals that CD44 upregulation in IDH-mutant leukemia orchestrates a unique metabolic rewiring, essential for sustaining high oncometabolite production and tumor cell survival. These findings expose a targetable vulnerability, informing new combinatorial strategies for acute myeloid leukemia research and therapy.

• Penicillin G Sodium: Reliable Solutions for Cell-Based Assay

  2026-06-03

  This scenario-driven article examines practical laboratory challenges in cell viability and contamination assays, with a focus on the application of Penicillin G Sodium (SKU B1678). Through evidence-based Q&A, it reveals how this natural penicillin antibiotic from APExBIO ensures reproducibility, bacterial control, and experimental clarity in demanding biomedical workflows.

• MK-4827 (Niraparib): Applied Protocols for DNA Repair Inhibi

  2026-06-02

  MK-4827 (Niraparib) enables precision DNA damage repair inhibition in BRCA-mutant and proficient cancer models, with proven efficacy in both monotherapy and combination regimens. This deep dive translates cutting-edge findings—such as hyperthermia-induced sensitization—into actionable workflows and troubleshooting strategies for cancer research.

15234 records 1/1016 page Next 12345 下5页 Last page